Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEurocell Regulatory News (ECEL)

Share Price Information for Eurocell (ECEL)

Share Price is delayed by 15 minutes
Get Live Data
104.00    -3.00 (-2.80%)
Bid:
106.00
Ask:
110.50
Spread: 4.50 (4.245%)
Market Cap: £102.49m
ECEL Live PriceLast checked at - London Stock Exchange

Intraday Eurocell Share Chart

Proposed Placing

15 Sep 2015 07:00

RNS Number : 0275Z
Peel Hunt LLP
15 September 2015
 

Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or Republic of South Africa or any other jurisdiction in which offers or sales would be prohibited by law.

Proposed placing of 15,000,000 ordinary shares in Eurocell PLC by H2 Equity Partners Fund IV

Cooperatief H2 Equity Partners Fund IV Holding W.A. ("H2") today announces its intention to sell 15 million ordinary shares ("Placing Shares") in Eurocell PLC ("Eurocell" or the "Company") to institutional investors (the "Placing"). The Placing Shares represent approximately 15% of Eurocell's entire issued share capital.

The Placing will be conducted by means of an accelerated bookbuild secondary placing to institutional investors. The books of the Placing will open with immediate effect. The final price at which the Placing Shares are to be sold will be agreed by Peel Hunt LLP ("Peel Hunt"), Canaccord Genuity Limited ("Canaccord Genuity") and H2 at the close of the bookbuild process, subject to a minimum price of 200 pence per Placing Share. The results of the Placing will be announced as soon as practicable thereafter. The timing of the closing of the books will be at the absolute discretion of Peel Hunt and Canaccord Genuity but the books will, in any event, be closed by 5pm on 15th September 2015. The Placing Shares are expected to be sold on a T+5 basis.

Post completion of the Placing, H2's remaining stake in Eurocell is expected to comprise approximately 22.1 million ordinary Eurocell shares, equivalent to approximately 22.1% of Eurocell's entire issued ordinary share capital. H2 remain firmly committed to Eurocell and have agreed to a further lock-in in respect of the balance of their ordinary shares in the Company, which will expire upon publication of the Company's audited results for the financial year ended 31 December 2015.

H2 has entered into a placing agreement with Peel Hunt and Canaccord Genuity under which Peel Hunt and Canaccord Genuity will act as joint bookrunners in relation to the Placing.

Enquiries:

Peel Hunt LLP +44 (0) 207 418 8900

 

Al Rae (ECM) +44 (0) 207 418 8914

Dan Webster (Corporate)

 

Canaccord Genuity Limited +44 (0) 207 523 8350

 

Piers Coombs (ECM)

Bruce Garrow (Corporate)

Chris Connors (Corporate)

 

The distribution of this announcement and the offer and sale of the Placing Shares in certain jurisdictions may be restricted by law. The Placing Shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the Placing Shares in such jurisdiction. No action has been taken by H2 or by Peel Hunt or Canaccord Genuity or any of their respective affiliates that would permit an offering of the Placing Shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful.

 

This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and dependencies, any State of the United States and the District of Columbia), Australia, Canada, Japan or Republic of South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this announcement or other information referred to herein comes, should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither this announcement nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States. There will be no public offering of any securities in the United States or in any other jurisdiction.

 

In member states of the European Economic Area ("EEA") which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer if made subsequently is directed exclusively at persons who are 'qualified investors' within the meaning of the Prospectus Directive ("Qualified Investors"). For these purposes, the expression 'Prospectus Directive' means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression '2010 PD Amending Directive' means Directive 2010/73/EU. In the United Kingdom this announcement is directed exclusively at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) who fall within Article 49(2)(A) to (D) of the Order, and (iii) to whom it may otherwise lawfully be communicated.

 

In connection with any offering, Peel Hunt or Canaccord Genuity and any of their respective affiliates acting as an investor for its own account may take up as a proprietary position any Placing Shares and in that capacity may retain, purchase or sell for their own account such Placing Shares. In addition they may enter into financing arrangements and swaps with investors in connection with which they may from time to time acquire, hold or dispose of Placing Shares. Neither Peel Hunt nor Canaccord Genuity intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

 

Peel Hunt which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting on behalf of H2 and no one else in connection with any offering of the Placing Shares and will not be responsible to any other person for providing the protections afforded to any of their clients or for providing advice in relation to any offering of the Placing Shares. Peel Hunt will not regard any other person as its client in relation to the offering of the Placing Shares.

 

Canaccord Genuity which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting on behalf of H2 and no one else in connection with any offering of the Placing Shares and will not be responsible to any other person for providing the protections afforded to any of their clients or for providing advice in relation to any offering of the Placing Shares. Canaccord Genuity will not regard any other person as its client in relation to the offering of the Placing Shares.

 

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Peel Hunt or Canaccord Genuity or by any of their affiliates or agents as to, or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

 

The price of shares and the income from them may go down as well as up and investors may not get back the full amount invested on disposal of the shares. Past performance is no guide to future performance and persons needing advice should consult an independent financial advisor.

 

This announcement includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "intends", "expects", "will", or "may", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Any forward-looking statements are subject to risks relating to future events and assumptions relating to Eurocell's business, in particular from changes in political conditions, economic conditions, evolving business strategy, or the retail industry. No assurances can be given that the forward-looking statements in this announcement will be realized. As a result, no undue reliance should be placed on these forward-looking statements as a prediction of actual results or otherwise.

Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or Republic of South Africa or any other jurisdiction in which offers or sales would be prohibited by law.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXNLFDDSEFF
Date   Source Headline
16th Mar 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
7th Mar 20237:00 amRNSBlock listing Interim Review
3rd Feb 20237:00 amRNSNon-executive Directors' Share Purchase Plan
31st Jan 20237:00 amRNSHolding(s) in Company
26th Jan 20237:00 amRNSYear End Trading Update
6th Jan 20237:00 amRNSCEO Announces Intention to Retire in 2023
15th Nov 20227:04 amRNSHolding(s) in Company
14th Nov 20227:00 amRNSHolding(s) in Company
10th Nov 20224:00 pmRNSHolding(s) in Company
8th Nov 20223:59 pmRNSDirectorate Change
26th Oct 20227:00 amRNSHolding(s) in Company
7th Oct 20227:00 amRNSChanges to Board Committee memberships
5th Oct 20222:00 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSTotal Voting Rights
5th Sep 20227:00 amRNSBlock listing Interim Review
5th Sep 20227:00 amRNSInvestor Presentation
1st Sep 20227:00 amRNSHalf-year Report
15th Aug 20223:00 pmRNSHolding(s) in Company
10th Aug 20223:45 pmRNSAppointment to the Audit & Risk Committee
13th Jul 20227:00 amRNSTrading Update
5th Jul 202212:25 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSTotal Voting Rights
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
21st Jun 202212:08 pmRNSDirectorate Change
25th May 20227:00 amRNSBlock Listing Application
16th May 20227:00 amRNSDirector/PDMR Shareholding
12th May 20224:00 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update and Board Update
14th Apr 20224:00 pmRNSDirector/PDMR Shareholding
14th Apr 20224:00 pmRNSDirector/PDMR Shareholding
8th Apr 20227:00 amRNSAnnual Financial Report
21st Mar 20227:00 amRNSInvestor Presentation
18th Mar 20227:00 amRNSPreliminary results for the year ended 31 Dec 2021
17th Mar 20227:00 amRNSNotice of Results and Audiocast
15th Mar 20223:05 pmRNSTransaction in Own Shares
9th Mar 20225:00 pmRNSBlock listing Interim Review
16th Feb 20227:00 amRNSAppointment of Joint Corporate Broker
21st Jan 20227:00 amRNSYear End Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights
1st Dec 20217:00 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSTrading Update November 2021
1st Nov 20217:00 amRNSTotal Voting Rights
1st Oct 20217:00 amRNSTotal Voting Rights
7th Sep 20214:00 pmRNSInvestor Presentation
7th Sep 20211:38 pmRNSBlock listing Interim Review
3rd Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSTotal Voting Rights
2nd Aug 20217:00 amRNSTotal Voting Rights
20th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.